RSV Vaccination Rates Lag Despite Success: What Pharmacists Need to Know for Next Season
Despite a significant reduction in RSV-related hospitalizations following the introduction of new vaccines in 2023, less than half of at-risk adults have received a dose. This gap presents a critical challenge – and opportunity – for pharmacists as they prepare for the next respiratory virus season. Data from the 2024-2025 season reveals a clear success story for these vaccines, but also underscores the urgent need for more targeted outreach and innovative vaccination strategies.
The Data Tells a Compelling Story
The 2024-2025 respiratory season saw a notable spike in RSV test positivity between November and January, peaking at nearly 11% according to the National Respiratory and Enteric Virus Surveillance System (NREVSS). While slightly lower than the 12.75% peak observed during Thanksgiving 2023, this sustained high positivity rate highlights the continued threat posed by the virus. Crucially, hospitalization rates, while still elevated, began a rapid decline in February, dropping to 0.3 per 100,000 by April. This decline is strongly correlated with the increasing availability and uptake of RSV vaccines.
Specifically, hospitalization rates for adults aged 65 and older peaked at 8.8 per 100,000 in early January 2025, down from 9.5 per 100,000 during the same period in the previous year. These figures demonstrate the protective effect of the vaccines, particularly for the most vulnerable population. Pharmacists can readily access this crucial data through the CDC’s RSV Hospitalization Surveillance Network (RSV-NET) to inform their local vaccination efforts.
Vaccination Coverage: Room for Improvement
While the initial rollout of Arexvy (GSK), Abrysvo (Pfizer), and mRESVIA (Moderna) was promising, vaccination rates remain suboptimal. By the end of the 2024-2025 season, approximately 47.5% of adults aged 75 and older had received an RSV vaccine. Coverage was lower for the 60-74 age group, at around 38.1%. These numbers, while representing an increase from the previous year, fall short of the levels needed to achieve widespread protection.
The majority of vaccine doses were administered in retail pharmacies – 1.76 million doses to those 75+ and 1.62 million to those 60-74 – highlighting the pivotal role pharmacists play in delivering this critical preventative care. However, the relatively low percentage of individuals reporting a definite intention to get vaccinated (8.0% for 75+ and 10.1% for 60-74) suggests a significant opportunity to address vaccine hesitancy and improve patient education.
Targeted Outreach is Key
The data suggests a need for more focused outreach strategies. Leveraging the predictable seasonal spike in RSV infections, pharmacists can proactively target vaccination campaigns in the weeks leading up to major holiday gatherings. Framing vaccination as a way to protect oneself and loved ones during these events could prove particularly effective. Furthermore, addressing common misconceptions about RSV and the vaccines – such as concerns about side effects or perceived low risk – is crucial.
Looking Ahead: Predicting Future Trends
Several factors suggest that the importance of RSV vaccination will only grow in the coming years. As the population ages, the number of individuals at high risk for severe RSV disease will increase. Furthermore, the potential for future RSV variants necessitates ongoing monitoring and adaptation of vaccination strategies. The CDC’s Weekly RSV Vaccination Dashboard will continue to be an invaluable resource for tracking vaccination trends and identifying areas for improvement.
One emerging trend to watch is the potential for combination vaccines. Researchers are exploring the possibility of developing a single vaccine that protects against multiple respiratory viruses, including RSV, influenza, and COVID-19. Such a vaccine could significantly simplify vaccination schedules and improve overall public health outcomes. The National Institutes of Health is actively involved in this research; more information can be found on their website: National Institute of Allergy and Infectious Diseases.
Ultimately, the success of RSV vaccination efforts hinges on the continued collaboration between healthcare professionals, public health agencies, and pharmacists. By leveraging data, embracing innovative strategies, and prioritizing patient education, we can significantly reduce the burden of this often-underestimated respiratory virus. What strategies will *you* implement this season to boost RSV vaccination rates in your community? Share your thoughts in the comments below!
